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Abstract
Background: Gliomas frequently contain mutations in the cytoplasmic NADP
+-dependent isocitrate dehydrogenase (IDH1)
or the mitochondrial NADP
+-dependent isocitrate dehydrogenase (IDH2). Several different amino acid substitutions recur at
either IDH1 R132 or IDH2 R172 in glioma patients. Genetic evidence indicates that these mutations share a common gain of
function, but it is unclear whether the shared function is dominant negative activity, neomorphic production of (R)-2-
hydroxyglutarate (2HG), or both.
Methodology/Principal Findings: We show by coprecipitation that five cancer-derived IDH1 R132 mutants bind IDH1-WT
but that three cancer-derived IDH2 R172 mutants exert minimal binding to IDH2-WT. None of the mutants dominant-
negatively lower isocitrate dehydrogenase activity at physiological (40 mM) isocitrate concentrations in mammalian cell
lysates. In contrast to this, all of these mutants confer 10- to 100-fold higher 2HG production to cells, and glioma tissues
containing IDH1 R132 or IDH2 R172 mutations contain high levels of 2HG compared to glioma tissues without IDH
mutations (54.4 vs. 0.1 mg 2HG/g protein).
Conclusions: Binding to, or dominant inhibition of, WT IDH1 or IDH2 is not a shared feature of the IDH1 and IDH2
mutations, and thus is not likely to be important in cancer. The fact that the gain of the enzymatic activity to produce 2HG is
a shared feature of the IDH1 and IDH2 mutations suggests that this is an important function for these mutants in driving
cancer pathogenesis.
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Introduction
Heterozygous point mutations in IDH1 and IDH2 occur in a
significant portion of human cancers. Affected cancer types include
gliomas of intermediate malignant grade (73–94%) [1,2] and acute
myeloid leukemias (AMLs, 16–22%) [3,4,5,6], and cases of IDH1
mutations have been reported in prostate cancer [7], acute
lymphoblastic leukemia, B type [7], colorectal cancer [8], and
melanoma [9]. The IDH1 mutations observed in cancer tissue are
specific for R132, a residue in the enzyme active site. R132H is the
most common IDH1 substitution in gliomas, followed by R132C,
R132S, R132L, and R132G. IDH2 is homologous to IDH1, and
IDH2 mutations in glioma are specific for R172, the residue that is
analogous to IDH1 R132. R172K, R172M, and R172G are the
IDH2 substitions observed in gliomas. The IDH2 R172 mutations
are rarer than the IDH1 R132 mutations in gliomas, and mutations
in either gene are mutually exclusive in cancer (for reviews, see
[10,11]). The frequent observation of heterozygous hotspot
mutations in IDH1 and IDH2 suggests that they are proto-
oncogenes that are activated by these mutations in cancer. In line
with this, two different molecular gains-of-function have been
demonstrated for several of the mutated forms of IDH1 and IDH2.
The first proposed function for IDH mutants is dominant
negative inhibition of WT IDH enzymes. IDH1 R132 and IDH2
R172 mutations inactivate the normal NADP
+-IDH activity of
IDH1 and IDH2 to convert isocitrate to a-ketoglutarate [2,12].
Furthermore, IDH1-R132H can bind to IDH1-WT, and the
resulting WT:mutant heterodimer has markedly lowered isocitrate
dehydrogenase activity at physiological isocitrate concentrations
(,80 mM) compared to WT:WT homodimers in vitro [13].
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e16812Since the IDH mutations observed in cancer are heterozygous,
it has been speculated that IDH1 and IDH2 mutants bind the
remaining IDH1-WT or IDH2-WT molecules in cells and exert a
dominant negative function. However, it is unclear whether
binding to IDH1-WT or IDH2-WT is shared by all of the glioma-
derived IDH mutants, or whether IDH mutants actually bind a
significant portion of IDH1-WT or IDH2-WT molecules to exert
this dominant negative function in cells. In one study, tumor tissue
from glioblastomas with IDH1 R132 mutations had 38% lower
NADP
+-IDH activity on average than tissue from glioblastomas
without IDH mutations [14]. However, it is unclear whether this
lowered activity reflects the loss of activity from the mutated IDH1
allele, or if it also reflects dominant negative lowering of the
activity from the remaining WT IDH1 allele or the WT IDH2.
The second proposed function for IDH mutants is that they gain
the neomorphic activity to reduce a-ketoglutarate to 2HG
[4,6,15]. However, this has not been demonstrated for all of the
recurrent IDH mutants, nor has it been determined whether
IDH2-mutated gliomas contain elevated 2HG levels.
The relative importance of either dominant negative activity or
2HG-producing catalytic activity for the IDH1 and IDH2 mutants
in cancer is unclear, and the mechanism by which either of these
gained functions may contribute to cancer pathogenesis remains
unknown. Examining the relevance of these two molecular
functions has the potential to identify therapeutic targets for
cancer treatment, and to inform future studies on the mechanism
of cancer pathogenesis for IDH-mutated cancer cells. To resolve
this issue, we focus on identifying shared functions for the IDH
mutations in cancer, and ruling out functions that are not shared,
for a panel of eight glioma-derived IDH mutants. We reasoned
that functions of the IDH mutants that are important in cancer
will be shared between all eight mutants, and that functions that
are not required for cancer pathogenesis may not be shared. We
show that binding to, and dominant negative inhibition of, IDH1-
WT or IDH2-WT is not a shared feature of the glioma-derived
IDH mutants, but that 2HG production and accumulation in
tumors is a common feature of these mutants.
Results
IDH1 R132 mutants bind IDH1-WT, but IDH2 R172
mutants poorly bind IDH2-WT
IDH1 and IDH2 function as homodimers, and IDH1 R132H
can bind to and dimerize with WT IDH1 in vitro [13]. However, it
is unclear whether other IDH1 R132 mutants can bind IDH1. To
determine this, we overexpressed IDH1-WT or one of five glioma-
derived IDH1 R132 mutants with C-terminal MYC and FLAG
tags in human oligodendroglioma (HOG) cells, a human glioma
cell line that does not contain IDH mutations [2]. We then
determined whether endogenous IDH1-WT coprecipitated with
the overexpressed forms of IDH1 by performing anti-FLAG
immunoprecipitation. Transgenic IDH1-WT and IDH1 R132
mutants were similarly able to bind and pull down endogenous
IDH1-WT (Fig. 1a). We next tested whether IDH1-R132H, the
most common IDH mutant in gliomas [2], could bind to other
IDH1-R132H molecules in cells. To do so, we first transfected
glioma cells with combinations of IDH1-WT and IDH1-R132H
with MYC-FLAG or EGFP tags. Then, we assayed the ability for
MYC-FLAG-tagged IDH1-WT or IDH1-R132H to pull down
EGFP-tagged IDH1-WT or IDH1-R132H. The formation of
IDH1 WT:R132H, WT:WT, and R132H:R132H was about
equal in this system (Fig. 1b).
Since IDH1 R132 mutants can bind IDH1-WT, we hypoth-
esized that the analogous IDH2 R172 mutants could bind
IDH2-WT. However, IDH2 R172 mutants were only weakly
able to pull down endogenous IDH2 compared to IDH2-WT in
these cells (Fig. 1c). Since binding to IDH1-WT may be an
important function for IDH1 R132 mutants in cancer [13], we
hypothesized that IDH2 R172 mutants may localize outside the
mitochondria and also bind IDH1-WT. However, neither IDH2-
WT nor IDH2-R172K was able to bind and pull down
endogenous IDH1, indicating that IDH1 and IDH2 cannot bind
to each other (Fig. 1d).
IDH mutants do not dominantly lower cellular IDH
activity
Purified IDH1-R132H:WT heterodimers have a lowered
isocitrate dehydrogenase reaction rate compared to IDH1-
WT:WT homodimers at low isocitrate concentration [13]. Based
on this, IDH1 and IDH2 mutants have been proposed to inhibit
the activity of the wild-type IDH1 or IDH2 allele in cancer cells in
a dominant-negative fashion. However, it is unknown whether
IDH1-R132H or other IDH1 and IDH2 mutants can lower the
activity of wild-type IDH1 or IDH2 in cells. Previous studies of the
effect of IDH1 and IDH2 mutant overexpression on endogenous
isocitrate dehydrogenase activity in cell lysates have been carried
out at relatively high substrate concentrations (400 mMo r
1.3 mM) [2,12]. At these high concentrations, mutant:WT
heterodimers have a similar reaction rate to WT:WT homodimers
[13]. Thus, in these studies, any dominant negative activity
exerted by mutant enzymes on the wild-type endogenous proteins
would be masked.
Both IDH1 and IDH2 have NADP
+-dependent isocitrate
dehydrogenase (NADP
+-IDH) activity, and no other mammalian
enzymes have this activity. Because of this, assays of NADP
+-IDH
activity on whole cell lysates reflect the combined activity of IDH1
and IDH2. To provide information on the proportion of NADP
+-
IDH activity contributed by IDH1 and by IDH2 in cells, we stably
transfected HOG cells with IDH1 shRNA or scrambled shRNA.
IDH1 expression was reduced by 90 percent in the IDH1 shRNA
cells, and the NADP
+-IDH activity was reduced by nearly half,
indicating that IDH1 accounts for nearly half of cellular NADP
+-
IDH activity (Fig. 2a). The remaining activity in IDH1 knockdown
cells may be supplied by the residual IDH1 enzyme and by IDH2.
To determine whether IDH1 and IDH2 mutants can
dominantly inhibit the activity of endogenous IDH1 and IDH2
enzymes, we assayed NADP
+-IDH activity of lysates of HOG cells
overexpressing IDH1-WT, IDH2-WT, or cancer-derived IDH1
R132 and IDH2 R172 mutants in the presence of 40 mM
isocitrate. Importantly, FLAG-MYC-tagged IDH1-WT and
IDH2-WT have previously been shown to have their native
enzyme activity in this setting [2], indicating that dimerization and
enzymatic activity are not affected by this epitope tag. 40 mM
isocitrate closely mimics the concentration of this metabolite in
cells [16]. Additionally, purified IDH1 R132H:WT heterodimers
have a significantly lower reaction rate than WT:WT homodimers
at this substrate concentration [13]. We therefore reasoned that
any inhibition of endogenous wild-type IDH1 or IDH2 by
transgenic IDH1 or IDH2 mutants would be apparent at this
substrate concentration. As expected, overexpession of IDH1-WT
or IDH2-WT greatly increased the total NADP
+-IDH reaction
rate at 40 mM isocitrate (Fig. 2b). However, transgenic IDH1
R132 and IDH2 R172 mutants had little effect on this activity
(Fig. 2b), showing that they do not dominant-negatively inhibit
IDH1-WT or IDH2-WT in this system. To validate this finding
and expand it to non-cancer cells, we repeated this experiment in
293T cells and found similar results (Fig. 2c).
Mutant IDHs Produce 2HG but Are Not DN
PLoS ONE | www.plosone.org 2 February 2011 | Volume 6 | Issue 2 | e16812Figure 1. IDH1 R132 mutants bind IDH1-WT, but IDH2 R172 mutants poorly bind IDH2-WT. (a) Whole cell lysates of HOG cells
overexpressing FLAG-MYC-tagged IDH1 proteins contain comparable amounts of endogenous IDH1. FLAG-IP of these lysates coprecipitates
endogenous IDH1-WT (lower anti-IDH1 band) along with the FLAG-MYC-tagged IDH1 proteins (anti-MYC band and upper anti-IDH1 band). (b) HOG
cells were transfected with FLAG-MYC-tagged IDH1-WT, IDH1-R132H, or a vector control (V) in combination with EGFP-tagged IDH1-WT or IDH1-
R132H. As expected, FLAG-IPs of these cells pull down FLAG-MYC-tagged IDH1 (middle band). Endogenous IDH1 (lower band) coprecipitates with
FLAG-MYC-tagged IDH1. EGFP-tagged IDH1 (upper band) also coprecipitates with FLAG-MYC-tagged IDH1. (c) Whole cell lysates of HOG cells
overexpressing FLAG-MYC-tagged IDH2 contain comparable amounts of endogenous IDH2. FLAG-IP of these lysates coprecipitates endogenous IDH2
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IDH1 or IDH2 could reduce total cellular NADP
+-IDH activity at
other concentrations of isocitrate at which mutant:WT heterodi-
mers have lowered activity, we also assayed the total cellular
NADP
+-IDH activity of the 293T cells expressing IDH1-R132H
or IDH2-R172K described above over a range of 0 to 80 mM
isocitrate. These mutants did not lower the overall NADP
+-IDH
activity compared to vector alone at any of the substrate
concentrations we assayed (Fig. 2d). These data indicate that
homologous expression of IDH mutants does not interfere with
normal, endogenous IDH1-WT or IDH2-WT. However, it is
possible that homologously expressed IDH mutants could have
limited interaction with endogenous IDH in cells. To address this
possibility, we determined whether an IDH1 R132 mutant could
inhibit IDH1-WT when both are expressed homologously. To do
so, we co-expressed IDH1-R132H and IDH1-WT in HOG cells,
and found that IDH1-R132H expression did not lower cellular
NADP
+-IDH activity of cells expressing IDH1-WT more than
vector alone (Fig. S1).
IDH mutants produce 2HG, which accumulates in IDH-
mutated gliomas
Overexpression of IDH1-R132H, as well as IDH2-R172K, in
mammalian cells leads to accumulation of 2HG in culture media
[6,15]. To confirm this finding and expand it to the other IDH
mutants found in gliomas, we measured 2HG levels in media
incubated with HOG cells overexpressing IDH1-WT, IDH2-WT,
or one of the recurrent cancer-derived mutants. To measure 2HG,
we adapted a protocol to use derivation with diacetyl-L-tartaric
anhydride to separate (R)-2-hydroxyglutarate, which is produced
by IDH mutants, from its enantiomer, (S)-2-hydroxyglutarate, on
a liquid chromatography (LC) column before performing tandem
mass spectrometry (MS/MS) [17]. (R)-2-hydroxyglutarate accu-
mulated over time in culture media for all mutants assayed
(Fig. 3a). To confirm this, we measured 2HG levels in media
incubated with 293T cells overexpressing the same IDH proteins
and found similar results (data not shown). We also determined the
levels of 2HG in lysates of HOG cells expressing IDH1 R132 and
IDH2 R172 mutants and found that 2HG was 10- to 100-fold
elevated in these lysates compared to vector alone (Fig. 3b)
Gliomas containing IDH1 R132 mutations have marked
elevations of 2HG [15]. Also, AMLs containing IDH1 R132 or
IDH2 R172 mutations have marked elevations of 2HG [4,6]. We
therefore reasoned that gliomas bearing IDH2 R172 mutations
would also have elevated 2HG. To test this, we analyzed 2HG in 12
glioma samples, including samples containing IDH1 R132H, IDH1
R132L, IDH2 R172K, IDH2 R172M or no IDH mutations. We
used a deuterated internal standard, [3,3,4,4-
2H4]-(R/S)-2-hydro-
xyglutarate (2HG-d4), to reliably quantify 2HG in glioma tissue
samples as described previously [17]. We found that all tumors
containing IDH mutations had markedly elevated (R)-2-hydro-
xyglutarate compared to tumors without IDH mutations (54.4 vs.
0.1 mg 2HG/g protein, p,0.001, Fig. 3c). This demonstrates for
the first time to our knowledge that gliomas with IDH2 R172
mutations can have elevated 2HG, that any cancer with IDH1
R132L or IDH2 R172M have elevated 2HG, and that 2HG in
cancer tissues is specific for (R)-2-hydroxyglutarate.
Discussion
IDH1 and IDH2 mutations arise early in cancer pathogenesis
and are specific for hotspot codons, suggesting that these
mutations have a shared oncogenic function that drives cancer
pathogenesis. We show that IDH mutants bind their correspond-
ing WT partners either approximately the same as (IDH1) or more
poorly than (IDH2) the WT version of the protein (Fig. 1a,c). Since
the property of binding to a WT partner is not shared among the
IDH mutants, it is unlikely that binding to a WT partner is an
important feature of the IDH mutations in driving cancer
pathogenesis.
Also, our data shows that IDH mutants do not exert a dominant
negative function in a model for IDH-mutated cancer cells. We
have shown that IDH1 WT:WT, WT:mutant, and mutant:mutant
dimers form in cells that express both mutant and WT forms of
IDH1 (Fig. 1b). Based on this, cancer cells that have heterozygous
IDH1 or IDH2 mutations would be expected to contain a mixture
of WT:WT, WT:mutant, and mutant:mutant IDH1 or IDH2
dimers. A previous study showed that the IDH1 WT:R132H
heterodimer has a lowered NADP
+-IDH activity at low concen-
trations of isocitrate [13]. Because the IDH1 R132 mutant must
bind IDH1-WT to form this heterodimer, IDH1-R132H could
dominant negatively inhibit IDH1-WT if a large amount of IDH1-
WT molecules in the cell bind to IDH1 mutants to form
heterodimers, rather than binding to other IDH1-WT molecules
to form WT:WT homodimers. The fact that we did not observe
dominant negative inhibition (Fig. 2b,c,d) suggests that a low
proportion of IDH mutant:WT heterodimers exist in cells
compared to WT:WT homodimers.
Why would few IDH WT:mutant heterodimers form in cells
compared to WT:WT homodimers? Differences in binding affinity
between IDH WT:WT, mutant:WT, and mutant:mutant dimers
could explain this phenomenon. For instance, if IDH mutant:WT
binding is weaker than mutant:mutant or WT:WT binding,
formation of the WT:WT and mutant:mutant homodimers would
outcompete formation of mutant:WT heterodimers. This is the
case for IDH2, since IDH2 R172 mutants have a weaker IDH2-
WT binding affinity than IDH2-WT itself (Fig. 1c). A difference in
binding to IDH1-WT was not observed between IDH1 R132
mutants and IDH1-WT by immunoprecipitation, although we
cannot rule out that a more subtle difference exists that was not
detected by this method.
While IDH mutants did not exert a dominant negative effect in
this system, our results show that 2HG production is a shared
function of the IDH mutants. In accordance with previous reports
for IDH1-R132H [15] and IDH2-R172K [6], we show that six
other IDH mutants produce 2HG when overexpressed in
mammalian cells (Fig. 3a,b). This is supported by the novel
finding that tumors with the rare IDH1-R132L and IDH2-
R172M mutations also accumulate 2HG (Fig. 3c). IDH mutations
are strongly associated with a wide range of transcriptomic and
genomic alterations in gliomas [18]. However, whether neo-
morphic IDH activity drives these changes, how it may do so, and
whether these alterations contribute to cancer pathogenesis remain
unclear. Also, while 2HG production is the most striking effect of
the neomorphic mutants, the consumption of NADPH or a-
ketoglutarate by the mutants may also have a role in cancer.
(anti-IDH2, lower band) along with the FLAG-MYC-tagged IDH2 (anti-IDH2, upper band and anti-MYC band). However, IDH2 R172 mutants pull down
endogenous IDH2-WT poorly compared to IDH2-WT. (d) FLAG-MYC-tagged IDH1-WT, IDH1-R132H, IDH2-WT, and IDH2-R172K were transfected into
HOG cells. FLAG-IP of lysates pulled down FLAG-MYC-tagged IDH1-WT, IDH1-R132H, IDH2-WT, and IDH2-R172K (anti-MYC bands). FLAG-MYC-tagged
IDH1-WT and IDH1-R132H also stained with anti-IDH1 (upper anti-IDH1 band). Endogenous IDH1-WT coprecipitated with FLAG-MYC-tagged IDH1-WT
and IDH1-R132H, but not with FLAG-MYC-tagged IDH2-WT and IDH2-R172K (lower anti-IDH1 band).
doi:10.1371/journal.pone.0016812.g001
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PLoS ONE | www.plosone.org 4 February 2011 | Volume 6 | Issue 2 | e16812Figure 2. Overexpression of IDH1 R132 and IDH2 R172 mutants does not reduce cellular NADP
+-IDH activity. Total NADP
+-IDH reaction
rate, which consists of the combined rates of IDH1 and IDH2, was measured in lysates by measuring the rate of conversion of NADP
+ to NADPH in the
presence of isocitrate. (a) Lysates of stable, clonal HOG cell lines containing an shRNA sequence targeted against IDH1 have lowered NADP
+-IDH
activity compared to a sister cell line expressing scrambled RNA from the same vector (V). (b) HOG cells were transfected with a vector control, IDH1-
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PLoS ONE | www.plosone.org 5 February 2011 | Volume 6 | Issue 2 | e16812How might IDH mutations contribute to cancer pathogenesis?
Mutant IDH1 expression can up-regulate hypoxia inducible factor
1a (HIF-1a), a transcription factor that has been implicated in
promoting angiogenesis and malignant behavior of cancer cells
[13]. Whether HIF-1a is up-regulated as a result of lowered
cellular levels of a-ketoglutarate as proposed by Zhao et al. [13], or
due to increased 2HG levels as hypothesized by Frezza et al. [19],
is unclear. Also, a role for HIF-1a in IDH-mutated cancer
pathogenesis has been questioned based on the fact that IDH-
mutated gliomas are generally not ‘‘angiogenic’’ as would be
expected for tumors with dysregulated HIF-1a [10], and because
IDH-mutated leukemias were not found to have increased
expression of HIF-1a target genes [5]. Recent studies have
suggested that IDH mutants impair TET2, an 5-methylcytosine
hydroxylase implicated in the regulation of epigenetic changes,
and that this impairment dysregulates cellular differentiation [20].
Future experiments may seek to test whether altered a-
ketoglutarate or 2HG concentrations can affect HIF-1a or
TET2 pathway members in vitro, and identify the cellular pathways
necessary for the IDH mutants to exert a cancer-related
phenotype. Such studies may help to pinpoint therapeutic targets
for treatment of IDH-mutated cancers.
Materials and Methods
Ethics Statement and Patient Samples
Glioma samples (Fig. 3c) were obtained from The Preston
Robert Tisch Brain Tumor Center Biorepository at Duke
University and their study was approved by the Duke Institutional
Review Board. Written informed consent was obtained for
banking and analysis of tissue samples from all patients involved
in this study. No animal work was conducted in this study.
Samples were analyzed previously for tumor type and IDH
mutation status [2].
Transfection
HOG cells were described previously [21], and 293T cells were
obtained from ATCC (Manassas, VA). pCMV6-Entry-IDH
vectors (OriGene, Rockville, MD) were used to overexpress IDH
cDNAs with C-terminal FLAG-MYC epitopes. pEGFP-N1
(Clontech, Mountain View, CA) was used to express IDH1
cDNAs with N-terminal EGFP. For transfection, 5610
6 cells were
plated in a 75 cm
2 flask 24 h before transfection with 20 mg (unless
otherwise indicated) of plasmid DNA using 50 ml Lipofectamine
2000 (Invitrogen, Carlsbad, CA). Stable HOG cell lines containing
IDH1 shRNA or control were constructed by transfecting HOG
cells with pSuperRetro vector (OligoEngine, Seattle, WA)
containing IDH1-specific hairpin or a scrambled sequence. Clones
were selected with 500 mg/ml G418 (Gibco/Invitrogen, Carlsbad,
CA) for 3 weeks and expanded after single cell dilution.
Immunoblot and immunoprecipitation
For immunoblots, anti-Myc (TA100010, OriGene) was used at
1:1000 dilution, anti-Flag (1:1000, TA100011, OriGene) at 1:1000
dilution, anti-IDHC (IDH1), N-20 (sc49996, Santa Cruz Biotech-
nology, Santa Cruz, CA) at 1:300 dilution, anti-IDH2, W16 (sc-
55668, Santa Cruz Biotechnology) at 1:100 dilution. Anti-
GAPDH (FL-335) (sc25778, Santa Cruz Biotechnology) at
1:10,000 dilution was used as a loading control for lysates. For
immunoprecipitation, 50 ml of anti-FLAG M2 affinity resin
(A2220, Sigma, St. Louis, MO) was rinsed 3610min with 1 mL
0.2% Triton-X100 PBS. 1 ml of cells were lysed 48 h post-
transfection in 0.2% Triton-X100 PBS. This lysate was added to
the resin, rotated at 4uC overnight, and then centrifuged at
10,000rpm, 4uC for 1 min. The pellet was washed by resuspension
in 1 ml 50 mM Tris HCl, 150 mM NaCl, pH 7.4 and re-
centrifuged 6x for IDH1 and 3x for IDH2. 80 ml 2x SDS 5% b-
mercaptoethanol loading buffer was added to the pellet, incubated
at 100uC for 5 min, and loaded on SDS-PAGE. Intensity of bands
in immunoblots were quantified using ImageJ (v1.43, available at
http://rsbweb.nih.gov/ij/, developed by Wayne Rasband, Na-
tional Institutes of Health, Bethesda, MD) to determine the level of
knockdown of IDH1 protein by shRNA expression.
Isocitrate dehydrogenase activity assays
Cells were harvested 48 h post-transfection and homogenized in
0.02% Triton-X100 PBS. This was sonicated 3x 20s and protein
concentration was quantified. For Figs. 2b and c, reactions were
performed using a final 200 ml reaction volume containing 10 mg
cell lysate, 33 mM Tris-Cl pH 7.5, 2 mM MnCl2, 107 mM
NADP
+,4 0 mM isocitrate (Ds-threo-isocitrate, monopotassium
salt, Sigma) at room temperature. The reaction mix without
isocitrate was first prepared in a 180 ml volume, checked on the
spectrophotometer to confirm that there was no activity, and then
started by adding 20 ml of 400 mM isocitrate. Reaction progress
was monitored by A340 nm for 1 h using a PolarSTAR Optima
(BMG Labtech, Offenburg, Germany). To titrate the concentra-
tion of isocitrate (Fig. 2d), a more sensitive, single-channel
spectrophotometer (UV-2501PC, Shimadzu, Kyoto, Japan) was
used to quantify low levels of activity. These reactions were
performed as described above, except 1 ml total reaction mix was
used, 20 mg lysate was used, 100 ml of 10x concentrated isocitrate
was added to start the reaction, and the reaction was monitored
for 1 min. Reactions were performed in triplicate. A no lysate
control was run along with each experiment, which confirmed that
activity was specific to reaction mixes that contain lysate (not
shown). NADPH production was calculated using an NADPH
extinction coefficient of 6.2610
3 M
-1 cm
-1.
2HG analysis
Quantification of 2-HG in media/tissues was performed by LC-
negative electrospray ionization-MS/MS as published previously
[17] with modifications to accommodate different sample
matrices. A racemic mixture of 2HG-d4 was prepared by mixing
1m g a-ketoglutarate-d6 (Sigma/Isotec) with 1 mg NaBH4
(Sigma) in 0.2 mL anhydrous MeOH (Sigma) followed by
30 min incubation at 60uC.
Media above cells was collected 0, 24, and 48 h after
transfection. Lysates were collected 48 hours after transfection.
To 20 mL of media or lysate, 2 mLo f6 5mg/mL of each 2HG-d4
enantiomer (internal standard) in water was added and the
mixture dried by vacuum centrifuge (50uC, 15 min). Dry residue
was treated with 50 mg/mL freshly prepared diacetyl-L-tartaric
anhydride (Sigma) in dichloromethane/glacial acetic acid (4/1 by
volume) and heated (75uC 30 min). After drying (50uC, 15 min)
the residue was dissolved in 100 mL LC mobile phase A (see below)
for analysis. For patient glioma tissue samples, 20 mg tissue,
200 mL deionized water, 1 mL chloroform, and a 4 mm ceramic
WT, an IDH1 R132 mutant, IDH2-WT, or an IDH2 R172 mutant, lysates were collected after 48 h, and total cellular NADP
+-IDH reaction rate at 40 mM
isocitrate was assayed. (c) The experiment in B was repeated with 293T cells. (d) 293T lysates transfected with vector control, IDH1-R132H, or IDH2-
R172K from C were assayed for NADP
+-IDH reaction rate at 0 to 80 mM isocitrate.
doi:10.1371/journal.pone.0016812.g002
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(Thermo-Savant, Waltham, MA). After centrifugation (5 min,
16,100 g), 200 mL of aqueous (upper) layer was transferred to a
1.5 mL glass vial and dried (50uC, 60 min), derivatized, and
reconstituted for LC-MS/MS analysis as described above in case
of media above the cells.
An Agilent 1200 series HPLC (Santa Clara, CA) was used for
liquid chromatography (LC) and a Sciex/Applied Biosystems API
3200 QTrap (Carlsbad, CA) was used for triple quadrupole mass
spectrometry (MS/MS). Mobile phase A: water, 3% acetonitrile,
280 mL ammonium hydroxide (,25%), pH adjusted to 3.6 by
formic acid (,98%). Mobile phase B: methanol. Analytical
column: Kinetex C18, 15064.6 mm, 2.6 mm, and SafeGuard
C18 463 mm guard-column from Phenomenex (Torrance, CA).
Column temperature: 45uC. Elution gradient at 1 mL/min flow
rate: 0–1 min 0% B, 1–2 min 0-100% B, 2–3.5 min 100%B, 3.5–
4 min 100-0% B, 4–10 min 0% B. Injection volume: 10 mL. Q1/
Q3 (m/z) transitions monitored: 363/147 (2HG) and 367/151
(2HG-d4). To calibrate, 0, 0.16, 0.54, 1.8, 6, and 20 mg/ml pure
(R)-2-hydroxyglutarate (Sigma) was prepared. These samples were
analyzed alongside experimental samples and accuracy acceptance
criteria was 85% for each but the lowest level (0.16 mg/mL, 80%).
In the case of glioma tissue samples, quantification was done by
using the signal resulting from the known concentration of 2HG-
d4 internal standard added to the sample prior to the sample
processing and analysis. A two-tailed Student’s t test assuming
equal variances was used to test for a significant difference in mean
2HG concentration between groups of samples.
Supporting Information
Figure S1 Co-expression of IDH1-R132H with IDH1-WT
does not lower NADP
+-IDH activity more than vector
alone. HOG cells were transfected with the indicated amounts of
pCMV6 vectors to express IDH1-WT, IDH1-R132H, or vector
alone (V), as indicated. 48 hours after transfection, cells were lysed
and total cellular NADP+-IDH activity was determined at 1.3mM
isocitrate. Results are from two independent measurements of
lysates and are representative of two independent experiments.
(PDF)
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